Cover Image
市場調查報告書

急性發炎:開發中產品分析

Acute Inflammation - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 271833
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
急性發炎:開發中產品分析 Acute Inflammation - Pipeline Review, H1 2014
出版日期: 2014年06月15日 內容資訊: 英文 50 Pages
簡介

急性發炎是身體對外傷(受傷或手術等)的即時性反應,通常會在二小時之內發生。這個自然防禦機制會增加患部的血液流量,造成體液滯留。常見的症狀有高燒、皮膚發紅、腫、功能喪失等。主要的治療方法包含非類固醇消炎劑,皮質類固醇,止痛藥等。

本報告提供急性發炎的治療藥開發情形調查分析,提供您開發中的產品概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

急性發炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • BioLineRx, Ltd.
  • Actelion Ltd
  • Forest Laboratories, Inc.
  • Italfarmaco S.p.A.
  • Alligator Bioscience AB
  • Anacor Pharmaceuticals, Inc.
  • Omeros Corporation
  • Dompe Farmaceutici S.p.A.
  • Peptinnovate Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ACT-389949
  • ATL-1222
  • CGEN-856
  • ADC-1004
  • DF-2156A
  • Selective Inhibitor of Pro Inflammatory Cytokine
  • AN-3485
  • PIN-201104
  • Small Molecule Targeting GPR32 for Acute Inflammation
  • Distamycin Derivatives

開發中產品的最新趨勢

暫停的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5142IDB

Global Markets Direct's, 'Acute Inflammation - Pipeline Review, H1 2014', provides an overview of the Acute Inflammation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Inflammation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Inflammation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Inflammation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Inflammation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Inflammation Overview
  • Therapeutics Development
    • Pipeline Products for Acute Inflammation - Overview
    • Pipeline Products for Acute Inflammation - Comparative Analysis
  • Acute Inflammation - Therapeutics under Development by Companies
  • Acute Inflammation - Therapeutics under Investigation by Universities/Institutes
  • Acute Inflammation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Acute Inflammation - Products under Development by Companies
  • Acute Inflammation - Products under Investigation by Universities/Institutes
  • Acute Inflammation - Companies Involved in Therapeutics Development
    • BioLineRx, Ltd.
    • Actelion Ltd
    • Forest Laboratories, Inc.
    • Italfarmaco S.p.A.
    • Alligator Bioscience AB
    • Anacor Pharmaceuticals, Inc.
    • Omeros Corporation
    • Dompe Farmaceutici S.p.A.
    • Peptinnovate Limited
  • Acute Inflammation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACT-389949 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATL-1222 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-856 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADC-1004 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DF-2156A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Selective Inhibitor of Pro Inflammatory Cytokine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-3485 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PIN-201104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule Targeting GPR32 for Acute Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Distamycin Derivatives - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acute Inflammation - Recent Pipeline Updates
  • Acute Inflammation - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Inflammation, H1 2014
  • Number of Products under Development for Acute Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Acute Inflammation - Pipeline by BioLineRx, Ltd., H1 2014
  • Acute Inflammation - Pipeline by Actelion Ltd, H1 2014
  • Acute Inflammation - Pipeline by Forest Laboratories, Inc., H1 2014
  • Acute Inflammation - Pipeline by Italfarmaco S.p.A., H1 2014
  • Acute Inflammation - Pipeline by Alligator Bioscience AB, H1 2014
  • Acute Inflammation - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014
  • Acute Inflammation - Pipeline by Omeros Corporation, H1 2014
  • Acute Inflammation - Pipeline by Dompe Farmaceutici S.p.A., H1 2014
  • Acute Inflammation - Pipeline by Peptinnovate Limited, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Acute Inflammation Therapeutics - Recent Pipeline Updates, H1 2014
  • Acute Inflammation - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Acute Inflammation, H1 2014
  • Number of Products under Development for Acute Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top